Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This retrospective observational study is designed to assess the response to treatment with
fulvestrant at a dose of 500 mg/month with a loading dose of 500 mg (LD-500), in terms of
progression free survival (PFS), overall survival (OS), and clinical benefit rate (CBR), in
post-menopausal women with Advanced Breast Cancer and estrogen receptor positive, who were
treated with this medicinal product and at said dose after having progressed with a previous
anti-estrogen therapy. During this study, a retrospective data collection will be carried out
using the information contained in the Clinical History of said patients, provided that the
treatment with fulvestrant at a dose of 500 mg and LD-500.